Clinical Trials Browser

Phase 2 × INDUSTRY × Multiple Indications Cancer × Clear all

NCT02297139 2023-05-06

Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib

Phase 2 Completed

17 enrolled 12 charts

Multiple Indications Cancer